

# UC Irvine

## UC Irvine Previously Published Works

### Title

New Directions in Treatments Targeting Stroke Recovery.

### Permalink

<https://escholarship.org/uc/item/9zz3w4qz>

### Journal

Stroke, 49(12)

### ISSN

0039-2499

### Authors

Lin, David J  
Finklestein, Seth P  
Cramer, Steven C

### Publication Date

2018-12-01

### DOI

10.1161/strokeaha.118.021359

### Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

## New Directions in Treatments Targeting Stroke Recovery

David J. Lin, MD; Seth P. Finklestein, MD; Steven C. Cramer, MD

Stroke is the leading cause of neurological disability in the United States and worldwide. Remarkable advances have been made over the past 20 years in acute vascular treatments to reduce infarct size and improve neurological outcome. Substantially, less progress has been made in treatments to enhance neurological recovery after stroke. However, several promising research directions have been identified for treatments targeting stroke recovery and are the focus of the current review (Figure).

Epochs of time poststroke can be divided into acute (hours-days), subacute (days-weeks), and chronic (months-years) based on the tissue response and biological programs that emerge during these time windows.<sup>1</sup> In contrast to acute stroke treatments, such as tPA (tissue-type plasminogen activator) and thrombectomy, for which the target is a clot, and where the goal is to salvage threatened brain tissue to limit injury, recovery treatments target surviving neural tissue with the goal of promoting neural repair.

Recovery trials are thus fundamentally different from acute stroke trials.<sup>2</sup> First, the time windows available for administering recovery-based treatments span much longer periods. These time windows enable detailed within-subject analyses before, during, and after treatment. Second, stroke deficits are multimodal (eg, combinations of motor, language, and other deficits) and recovery is modality-specific, meaning that different deficits recover with different rates and extents.<sup>3</sup> Accordingly, recovery trials often use modality-specific end points (such as the Fugl-Meyer [FM] Motor Scale), in addition to global outcome measures (such as the modified Rankin Scale [mRS] or the National Institutes of Health Stroke Scale [NIHSS]) that lump together all aspects of neurological function and are used in acute stroke trials. Third, recovery trials have issues often not shared with other stroke research domains, such as variable standards of care, patient access and retention, difficulty with experimental blinding (particularly in the study of behavioral interventions), and importance of concomitant experiences<sup>4</sup> (Table).

Spontaneous behavioral recovery occurs after stroke but is variable. The molecular and cellular mechanisms of this recovery have been extensively reviewed. Several treatment approaches in clinical translation aim to improve stroke recovery. Here, we review contemporary approaches to

therapeutically enhancing stroke recovery, focusing on recent trials. For this review, we define stroke recovery treatments as nonvascular treatments initiated in the subacute to chronic phases (days to years) after stroke. Our intent is not to be comprehensive, but to highlight select examples of promising approaches and directions with an acknowledged emphasis on motor recovery. It should be noted that to date no small molecule or biologic has been approved by the Food and Drug Administration to promote stroke recovery.

### Conventional Therapies

Conventional therapies for patients recovering from stroke include physical, occupational, and speech therapy. These are delivered across numerous care settings. The duration, intensity, and type of conventional therapy are highly variable in the United States, complicating the design of control groups in stroke rehabilitation trials. Indeed, one of the research priorities for stroke rehabilitation and recovery is better reporting and standardization of usual care in trials.<sup>1</sup>

Two specific interventions for stroke recovery with promising initial evidence emerging from conventional therapies include mirror therapy and constraint-induced movement therapy (CIMT).<sup>5</sup> Mirror therapy, or prism adaptation therapy, uses simple equipment to focus a patient's attention on a neglected hemifield. Mirror therapy, generally provided as an adjunct to conventional therapy, can improve motor function and reduce pain<sup>6</sup> and might improve activities of daily living.<sup>7</sup> Mirror therapy studies have been limited by small sample sizes and methodological limitations. Larger, more rigorous trials are needed. CIMT involves intensive rehabilitation therapy to overcome learned disuse by an affected arm, with concomitant constraint of the unaffected arm. EXCITE (Extremity Constraint Induced Therapy Evaluation)<sup>8</sup> was a phase 3 trial that found evidence that CIMT improved motor function, surpassing the minimally clinically important difference (MCID) in the Wolf Motor Function Test among patients in early chronic stroke. The timing of CIMT is important, as early application (10 days poststroke) was not more effective than traditional therapy.<sup>9</sup> Overall, there is moderate evidence that CIMT may be effective<sup>10</sup> for poststroke recovery, but specific protocols and timing have yet to be defined for widespread clinical adoption.

Received May 12, 2018; final revision received September 23, 2018; accepted October 4, 2018.

From the Division of Neurocritical Care and Emergency Neurology, Department of Neurology, Center for Neurotechnology and Neurorecovery, Massachusetts General Hospital, Boston (D.J.L.); Stroke Service, Department of Neurology, Massachusetts General Hospital, Boston (S.P.F.); and Department of Neurology, University of California, Irvine (S.C.C.).


Correspondence to Steven C. Cramer, MD, University of California Irvine, 843 Health Sciences Rd, Hewitt Hall, Room 1331, Irvine, CA 92697. Email [scramer@uci.edu](mailto:scramer@uci.edu)

(*Stroke*. 2018;49:3107-3114. DOI: 10.1161/STROKEAHA.118.021359.)

© 2018 American Heart Association, Inc.

*Stroke* is available at <https://www.ahajournals.org/journal/str>

DOI: 10.1161/STROKEAHA.118.021359



**Figure.** Summary of current experimental treatments for stroke recovery and their readiness for incorporation into clinical practice based on synthesis of current evidence. Readiness for clinical application ranges from preclinical development (ie, in animal studies only, red) to broad clinical application (green).

**Small Molecules**

The 2 classes of drugs that have been most investigated as stroke recovery treatments to date are serotonergic and dopaminergic. Building on prior smaller studies, the FLAME study (Fluoxetine for Motor Recovery After Acute Ischemic Stroke) was a double-blind, placebo-controlled trial in which 118 patients with weakness after ischemic stroke were randomized to 3 months of oral fluoxetine or placebo, 5 to 10 days poststroke.<sup>11</sup> Patients with clinical depression were excluded. Those randomized to fluoxetine showed significantly greater motor recovery to 90 days poststroke on the FM Motor Scale than those receiving placebo (a 9.8 point boost in recovery on the 100 point total FM for upper+lower extremities, largely driven by the upper extremity where fluoxetine-related gains exceeded the MCID of 5.25 points in chronic stroke<sup>12</sup>), as well as a significantly less disability as measured by the mRS; interpretation is complicated by mild baseline imbalances favoring the fluoxetine group. A meta-analysis of 52 trials of selective serotonin reuptake inhibitors (SSRIs) after stroke found that at the end of treatment, patients receiving an SSRI were less likely to be dependent, disabled, neurologically impaired, depressed, or anxious and that favorable effects were greater in participants who were depressed at randomization.<sup>13</sup> Phase III trials examining SSRIs for stroke recovery are ongoing. Several mechanisms might account for the potential efficacy of SSRIs for stroke recovery, including reducing neural inflammation,

enhancing neurotropic effects, and modulating excitatory/inhibitory synaptic and cortical network balance.<sup>14,15</sup>

Given their well-established role in reward, learning, and neural plasticity, dopaminergic drugs have also been investigated for poststroke recovery. In 2001, a single-center (inpatient rehabilitation facility), randomized, placebo-controlled study of 53 patients with ischemic stroke that occurred 3 weeks to 6 months previously showed that a dopaminergic drug (Sinemet 100 mg/d) improved motor recovery measured using the Rivermead Motor Assessment.<sup>16</sup> More recently, the Dopamine Augmented Rehabilitation in Stroke trial was a multicenter, randomized, double-blinded, placebo-controlled trial with some pragmatic design features that examined 6 weeks of Sinemet 100 mg/d given before rehabilitation therapy in 593 patients recruited 5 to 42 days poststroke and found no difference between groups in the primary end point, walking independently.<sup>17</sup> Overall, stroke recovery studies with dopaminergic drugs have been mixed, likely reflecting complex interactions between learning, reward, environment, psychology, cognition, and genetics.<sup>18</sup> Stroke recovery is not a one-size-fits-all science, and so these results suggest the need to identify the optimal target population and conditions for therapies targeting dopaminergic neurotransmission.

Other small molecules, including noradrenergic<sup>19</sup> and cholinergic<sup>20</sup> drugs, have recently been explored for poststroke recovery. Amphetamines have been extensively studied, with

**Table. Main Points**

Stroke recovery trials target a different biology with a different time course as compared to acute stroke trials.
Stroke recovery trials target brain tissue, not vasculature.
Acute phase treatments (reperfusion, neuroprotection) have a time window measured in minutes and hours, whereas recovery treatments have time windows measured in days, week, months, or years.
Recovery treatments are not targeted to rescue dying brain tissue but rather to promote neural repair in remaining tissue.
Many new promising strategies are on the horizon for stroke recovery.
Trials of treatments targeting stroke recovery benefit from employing modality-specific end points to obtain the granularity needed to measure differences in recovery across different neural systems (eg, recovery of language vs gait).
The time window for many recovery trials affords the opportunity to measure behavior at baseline and thus change in behavior, which in turn enables within-subject assessment of recovery.
The choice of the study population for recovery studies can strongly influence how well preclinical results are accurately translated and how well study hypotheses are truly tested.

mixed results, and a meta-analysis suggested that too few patients have been studied to draw conclusions.<sup>21</sup> Building upon favorable preclinical studies,<sup>22</sup> a phase IIa trial in France and Spain (<https://www.clinicaltrials.gov>; unique identifier: NCT02928393) of Basmisanil, a gamma-aminobutyric acid negative allosteric modulatory drug, was initiated but was terminated prematurely after 9 months (enrollment was slow—only 5 patients had been enrolled towards the goal of 95). A key insight from preclinical studies of neurotransmitter strategies is that a drug that improves recovery when initiated days after stroke onset can cause poorer outcomes if initiated too early,<sup>22,23</sup> reaffirming a longstanding observation in stroke recovery pharmacology that recovery drugs often have biphasic effects depending on time of initiation poststroke.

Few traditional and alternative medicines have been studied using formal research methods. One exception is the CHIMES study (Chinese Medicine Neuroaid Efficacy on Stroke Recovery),<sup>24</sup> a multicenter, double-blind, placebo-controlled clinical trial that randomized 1100 patients to 3 months of Neuroaid versus placebo, provided in the form of 3 daily doses of 4 oral capsules each. Neuroaid is a traditional Chinese medicine containing extracts of 9 herbal and 5 animal components. Patients started therapy within 72 hours of stroke onset. No difference between treatment arms was seen in the primary outcome measure, shift in the mRS at 3 months.

In summary, some small molecules are ready for late-phase trials and indeed are underway, whereas others are in earlier stages of development or require study with respect to specific patient subgroups or conditions. Timing of drug initiation is critical and can be informed by preclinical studies, as well as time window-finding studies in humans. Personalized medicine approaches can likely maximize benefit from small molecules for promoting stroke recovery, for example, enrolling subjects with attention to key genetic factors or pairing drug exposure with optimized reward or training. Combining small molecules with appropriate repetitive neurorehabilitation training may also be promising.

## Growth Factors

After stroke, many growth factors show increased levels for several weeks, playing a critical role in spontaneous neural repair through mechanisms that include neural sprouting and new synapse formation, angiogenesis, reduced apoptosis, stem cell proliferation, and immunomodulation.<sup>25</sup> One strategy to promote stroke recovery, therefore, is to increase levels of key growth factors.<sup>26</sup> Numerous preclinical stroke studies suggest that administration of exogenous growth factors  $\geq 24$  hours poststroke significantly improves outcome, for example, using fibroblast growth factor,<sup>27</sup> brain-derived neurotrophic factor,<sup>28</sup> epidermal growth factor plus erythropoietin,<sup>29</sup> or beta-human chorionic gonadotropin (b-hCG) followed by erythropoietin.<sup>30</sup>

Systemic erythropoietin enters the brain and when introduced with a delay after stroke (eg,  $\approx 24$  hours) can improve outcomes.<sup>31</sup> Favorable effects of this growth factor have been described in other preclinical studies that used sequential administration of epidermal growth factor<sup>29</sup> or b-hCG<sup>30</sup> followed by erythropoietin, beginning 1 to 7 days after stroke. This approach was studied in the BETAS study (B-hCG+Erythropoietin

in Acute Stroke), a single-dose, open-label, noncontrolled safety trial of b-hCG (initiated 1–2 days poststroke) followed by intravenous erythropoietin (initiated 7–8 days poststroke), which successfully demonstrated safety.<sup>32</sup> The REGENESIS Study (Study of NTx™-265: Human Chorionic Gonadotropin [hCG] and Epoetin Alfa [EPO] in Acute Ischemic Stroke Patients)<sup>33</sup> was intended to be a randomized, placebo-controlled, double-blind proof of concept study of sequential b-hCG and erythropoietin using the BETAS study treatment schedule. This trial was put on hold because of concerns arising from a previous acute neuroprotection stroke trial<sup>34</sup> that initiated erythropoietin  $< 6$  hours after stroke onset and found increased drug-related mortality rates, despite the fact that the REGENESIS trial targeted a different time window and biology (erythropoietin initiated  $< 6$  hours after stroke in the acute trial versus REGENESIS trial which waited until 7–8 days poststroke). As a result, the REGENESIS trial was modified to be a dose-ranging safety study, and treatment groups did not differ in NIHSS score change at day 90. Growth factors are likely appropriate for further clinical study—development would benefit from clearer direction from preclinical studies for insights into mechanism of action (informing target human population), dosing, and optimal timing.

## Monoclonal Antibodies

In the central nervous system, 3 inhibitors (MAG [myelin-associated glycoprotein], oligo-myelin glycoprotein, and neurite outgrowth inhibitor-A) increase levels poststroke and result in lack of a permissive growth environment.<sup>35</sup> Monoclonal antibodies can neutralize these inhibitors by modulating activity in targeted signaling pathways, thus promoting axonal growth and potential recovery. One study<sup>36</sup> randomized 42 patients with stroke to 2 rounds (24–72 hours poststroke and 9 days later) of placebo versus 1 of 3 dose levels of intravenous GSK249320, a humanized IgG1 monoclonal antibody to MAG with disabled Fc region. No safety concerns were identified, and results suggested that the antibody improved gait recovery. A subsequent phase II study<sup>37</sup> compared the highest intravenous GSK249320 dose level to placebo in 134 patients with stroke 24 to 72 hours prior. Although administration of the antibody resulted in lower free serum MAG levels, the primary end point, change in gait velocity from baseline to day 90, did not differ between groups. Effective antibody activity was confirmed in the periphery but was not assessed in the central nervous system. In summary, monoclonal antibodies would benefit from further preclinical development followed by further early phase clinical study.

## Cellular Therapy

Cell treatments have multiple effects in the poststroke brain. Transplanted cells might integrate into the existing brain architecture replacing cells lost to stroke; secrete cytokines, growth factors, and extracellular matrix proteins; or modify systemic immune responses to stroke aiding functional recovery. In a randomized, double-blind, placebo-controlled Phase 2 study, Hess et al<sup>38</sup> delivered allogeneic marrow-derived cells intravenously to 126 patients early (24–48 hours) after ischemic stroke. Cell administration was safe, but no significant efficacy signal was seen in the primary end point: excellent outcome at

day 90 (mRS score 0–1, NIHSS score 0–1, and Barthel score  $\geq 95$ ). Post hoc analysis at 1-year found a difference in excellent outcome (23% cell-treated versus 8% placebo;  $P=0.02$ ).

In a Phase 1/2 study, Kalladka et al<sup>39</sup> stereotactically implanted allogeneic immortalized human fetal neurons into the ipsilesional putamen adjacent to focal infarcts in 11 men with stable neurological deficits 6 to 60 months after ischemic stroke. There were 3 serious adverse events during the first month postprocedure: 2 asymptomatic intracranial hematomas attributed to the procedure and 1 symptomatic infarct attributed to preprocedure suspension of antiplatelet drugs. Nonserious adverse events were mostly mild. Several patients showed treatment-related improvement, including on NIHSS, Ashworth scale, and Barthel Index.

In a single-arm, open-label study, Steinberg et al<sup>40</sup> stereotactically implanted allogeneic modified marrow-derived mesenchymal cells into tissue surrounding focal infarcts in 18 patients with stable deficits 6 to 60 months after ischemic stroke. Cell implantation appeared safe, with reversible adverse events largely related to the surgical procedure. During 1-year follow-up, significant improvements were seen in the European Stroke Scale, NIHSS, and FM scores, with no significant changes in mRS.

In summary, early studies suggest that systemic and intracranial cell administration is feasible and may prove safe and effective as treatments for promoting neurological recovery early and late after stroke. Optimal dose, route, and timing of cell administration remain underexplored. Further randomized, double-blind, placebo-controlled trials are needed and are ongoing.

## Brain Stimulation

Several forms of brain stimulation have been investigated to enhance recovery after stroke, most in small studies. Some aim to increase activity, for example, with high-frequency repetitive transcranial magnetic stimulation,<sup>41</sup> whereas others aim to reduce activity in areas thought to have an undesired suppressive effect, for example, with low-frequency repetitive transcranial magnetic stimulation.<sup>42</sup> Similar approaches have been advanced for transcranial direct current stimulation,<sup>43</sup> where electrodes broadly apply current through the scalp in the treatment of several different types of poststroke deficits including motor, language, memory, and neglect. An advantage of transcranial direct current stimulation is it is readily applied during rehabilitation. Meta-analyses have concluded that more evidence is needed to establish benefit.<sup>44,45</sup> Two recent studies showing positive effects of transcranial direct current stimulation after stroke raise enthusiasm, one targeting dysphagia during the acute stroke hospitalization<sup>46</sup> and the other targeting chronic aphasia.<sup>47</sup> These highlight issues of capitalizing on anatomic substrates of neurological function (eg, bihemispheric control, for swallowing; unilateral dominant hemisphere control, for language), as well as importance of considering timing of intervention poststroke.

Other approaches for brain stimulation are under study, including deep brain stimulation. A phase III trial did not find a significant benefit from epidural cortical stimulation combined with rehabilitation compared with rehabilitation alone in

patients with chronic stroke.<sup>48</sup> Vagus nerve stimulation has been hypothesized to enhance brain plasticity, possibly by modulating activity in neurotransmitter systems, such as acetylcholine and norepinephrine.<sup>49</sup> A recent randomized human clinical trial of vagal nerve stimulation paired with rehabilitation demonstrated safety and feasibility,<sup>50</sup> and efficacy trials are ongoing.

To advance brain and nervous system stimulation for the treatment of stroke recovery, further clinical and possibly preclinical studies (preclinical studies have been limited to date) are needed to inform mechanism, dose, intensity, and optimal targets to maximize effects.

## Robotics

Robots are promising for stroke rehabilitation because they can deliver consistent, programmable, and high-intensity motor therapy, and furthermore can use sensors to measure movement kinematics. Numerous robotic systems have been studied.<sup>51</sup> A 2010 multicenter study of 127 patients conducted within the Veterans Health Administration system showed that robot-assisted therapy did not significantly improve motor status at 12 weeks, the primary end point, as compared with usual care or intensive therapy. A delayed favorable effect as compared with usual care, however, was suggested in secondary analyses for 36 weeks.<sup>52</sup> This study may have been limited by its choice of study population, enrolling patients with severe deficits in the chronic phase poststroke, among whom producing substantial benefits is challenging. Numerous other studies spanning different recovery stages for the past 20 years have demonstrated economic feasibility<sup>53</sup> and therapeutic benefits of robot therapy. Benefits of robot-assisted therapy for the upper extremity, however, are attributable to the intensity and repetition of movement practice,<sup>54</sup> and robot-mediated therapy has not demonstrated clear additional benefits when compared with physical therapy when intensity and number of movement repetitions have been matched.<sup>55</sup> Moreover, a recent Cochrane review of robot-assisted and electromechanical arm training devices for improving arm function after stroke found only low-quality evidence that such interventions improve activities of daily living.<sup>56</sup>

For the lower extremity, meta-analyses have shown that adding electromechanical-assistance (robot-assistance) to body weight support increases the odds of patients becoming independent with walking.<sup>57</sup> However, a large clinical trial did not find body weight supported treadmill training to be superior to progressive exercise at home managed by a physical therapist in patients 2-months poststroke.<sup>58</sup> American Heart Association/American Stroke Association Guidelines describe Class IIb evidence supporting mechanically assisted walking with body weight support for patients who are non-ambulatory after stroke.<sup>59</sup>

Overall, Phase 2 and possibly Phase 3 studies of robotics for stroke recovery are needed that enroll populations most likely to benefit or that test engineering approaches targeting improved functional outcomes using methods that build on the unique strengths of robots. Further development of robotic interventions might also include adjusting robot movements to patterns of disrupted movements and linking robot assistance to cortical activity (ie, brain-computer interfaces [BCI]).



## Brain-Computer Interfaces

When a lesion is severe, one potential approach to restoring voluntary behavior is to capture signals from intact cortex and bypass the lesion. Some advocate a surgical approach. A recent study in patients with spastic arm paresis due to various diagnoses (25% were because of stroke), an average of 15 years after the event showed that C7 nerve transfer from the nonparalyzed to paralyzed body side was associated with a 15 point increase in the FM arm score in the affected arm, exceeding the MCID for the upper extremity of 5.25 points in chronic stroke<sup>12</sup> and with sustained improvements as compared to controls (rehabilitation alone) at 1 year.<sup>60</sup>

An alternative approach to lesion bypass is a BCI. A BCI is a system that may or may not be noninvasive and that translates central nervous system signals into command signals for a technological device. The components of a BCI include devices for recording neural signals (sensors), the process of translating neural signals into command signals (neural decoding), devices for executing command signals (effectors), and the feedback provided to the user (feedback). Using BCI systems, people with neurological disease have successfully controlled computer cursors to regain communication and robotic prosthetics to restore movement.<sup>61</sup> A complementary goal of BCI is to enhance rehabilitation therapy effects.<sup>62</sup> The hypothesis is that training patients to produce normal brain activity patterns through feedback reinforcement or linking neural activity directly to sensory feedback of intended actions engages activity-dependent Hebbian neuroplasticity mechanisms and thereby restores native neurological functions. Initial studies in patients with chronic stroke have been promising, for example, electroencephalography-BCI training with an upper extremity orthosis produced a 3.4-point significant positive difference in the FM arm motor score compared with controls. Although shy of the MCID, behavioral gains in the experimental group correlated with adaptive changes in functional magnetic resonance imaging neural activity pattern, arguing that BCIs may induce clinically useful neuroplastic changes.<sup>63</sup> Another recent study<sup>64</sup> showed that use of an electroencephalography-driven exoskeleton to open and close the affected hand using signals from the contralesional (unaffected) hemisphere significantly improved arm function (6.2 point increase on the Action Research Arm Test score, exceeding the 5.7 point MCID<sup>65</sup> in chronic stroke). This study was notable given the use of signals from the unaffected hemisphere and delivery of therapy at home. Advances in BCI will benefit from a deeper understanding of how to facilitate personalized neural signals to enhance neuroplasticity, as well as a more nuanced understanding of circuit function in spontaneous recovery after stroke. More generally, the paradigm of closed-loop neurotechnological devices, in which sensing neural activity is coupled with effecting change in the nervous system, is a promising neurorehabilitation approach. Further preclinical study and early phase clinical development are needed.

## Telerehabilitation

Task-based practice improves outcomes after stroke in a dose-dependent manner and also provides the behavioral component of the experience-dependent plasticity that is facilitated by many restorative therapies. However, patients often do not

receive large doses of supervised practice because of issues such as cost, difficulty traveling to appointments, and regional provider shortages. Telehealth might provide new means to achieve high doses of therapy in an accessible manner using communication technologies. One recent study evaluated a home-based telerehabilitation system in patients with chronic hemiparetic stroke with onset 3 to 24 months prior.<sup>66</sup> Enrollees received 28-days of telerehabilitation prescribed and supervised by licensed therapists using a system delivered to the patient's home, each day consisting of 1 structured hour focused on individualized exercises and games, stroke education, plus an hour of free play. Compliance was excellent: participants engaged in therapy on 97.9% of assigned days, a substantial improvement over traditional home exercise programs. Arm repetitions averaged 879 per day, far exceeding the 32 repetitions found with standard of care therapy<sup>67</sup> and approximating the several hundred movements per day found in primate studies as important to achieving optimal post-stroke motor cortex plasticity.<sup>68</sup> Arm motor status showed significant gains, with half of the participants exceeding the arm motor FM score MCID. This approach did not require computer skills, levels of which were unrelated to motor gains or system use. A multisite phase II trial is now underway (<https://www.clinicaltrials.gov>; unique identifier: NCT02360488). Meta-analyses of telerehabilitation after stroke have found either better or similar effects when compared with conventional in-person therapy but have noted high heterogeneity in treatment content across studies.<sup>69,70</sup> Further clinical development of telerehabilitation to optimize dose and standardize protocols is warranted before late-phase clinical trials.

## Virtual Reality and Movement Sensors

There is converging evidence that high-dose, repetitive, task-oriented, and task-specific training is beneficial, at least for selected patients after stroke.<sup>71,72</sup> The key is not simply a greater number of repetitions but also task salience and specific attention to time poststroke and external environment.<sup>73–76</sup> Virtual reality (VR), ranging from nonimmersive to fully-immersive depending on the degree to which the user is isolated from his or her physical surroundings when interacting virtually, has been used as an alternative and as an adjunct to conventional rehabilitation. VR provides a scalable means to deliver high-intensity, task-specific training, as well as real-time feedback (ie, rewards for positive trials) potentially with enhanced salience. However, the evidence for efficacy of VR to date has been mixed.<sup>77–80</sup> Well-designed studies that build on prior work are needed, possibly maximizing salience to individual patient factors.

Movement sensors are another means of providing feedback with the goal of motivating greater skills practice and thus improving rehabilitation. In this regard, lower extremity sensors providing simple measures of physical activity and gait are more developed than upper extremity sensors, for which accurately characterizing reaching and grasping movements represents an ongoing computational challenge.<sup>81</sup> In one lower extremity sensor feasibility study, participants were given feedback of walking metrics via ankle sensors. This augmented feedback did not increase time spent practicing or improve walking outcomes in a rehabilitation setting as compared to

therapists providing feedback on walking speed alone (without the use of ankle sensors).<sup>82</sup> A recent review found some evidence that lower extremity wearable sensors improved outcomes, but the design of studies included was highly variable.<sup>83</sup> As with VR, additional earlier phase studies are needed, particularly those building on principles of personalized intervention.

## Summary and Future Directions

This review highlighted contemporary treatment approaches aimed at improving recovery after stroke. Development of stroke recovery treatments will depend on increased understanding of the complex events underlying recovery and development of methods to measure treatment effects in human patients. A key issue is optimal treatment timing, as specific critical periods for most interventions have not yet been defined. Trial design is also paramount, for example, end points targeting a single domain (motor, language, etc) may be more informative than global outcome measures that combine data from multiple different domains. Outcome measures benefit from having sufficient granularity to detect useful functional gains and being informative about the biology of recovery—global outcome measures, such as the mRS, may have critical shortcomings in this regard. As the efficacy and mechanism of individual treatments targeting stroke recovery are better understood, combinations of existing and novel therapies will warrant investigation.

Stroke recovery trials offer the opportunity for rigorous testing, for example, at baseline as entry criteria or stratification variables. Serum, genetic, imaging, and neurophysiologic data may be useful as predictors.<sup>84</sup> For example, motor response to transcranial magnetic stimulation<sup>85</sup> differentiates patients likely to experience spontaneous motor recovery from those who will not. An imaging-based measure of corticospinal tract injury can prospectively identify responders to rehabilitation therapy in chronic stroke.<sup>86</sup> Some of these measures can be serially collected as biomarkers of treatment effect.

The field of stroke recovery continues to benefit from the combination of perspectives of clinicians caring for stroke patients, as well as the scientists elucidating biological mechanisms of recovery and developing new recovery-promoting technologies. These groups bring invaluable insights.

## Sources of Funding

This work was supported by grants from the National Institutes of Health (R25NS065743, R44NS095381, and K24HD074722).

## Disclosures

Dr Lin has consulted for Boehringer Ingelheim; Dr Cramer, for MicroTransponder, Roche, Dart Neuroscience, Neurolutions, Regenera, Abbvie, SanBio, Constant Pharmaceuticals, and TRCare; and Dr Finklestein, for Constant Pharmaceuticals and AZTherapies, and he is a Principal in Stemetix.

## References

- Bernhardt J, Hayward KS, Kwakkel G, Ward NS, Wolf SL, Borschmann K, et al. Agreed definitions and a shared vision for new standards in stroke recovery research: the Stroke Recovery and Rehabilitation Roundtable taskforce. *Int J Stroke*. 2017;12:444–450. doi: 10.1177/1747493017711816

- Dobkin BH, Carmichael ST. The specific requirements of neural repair trials for stroke. *Neurorehabil Neural Repair*. 2016;30:470–478. doi: 10.1177/1545968315604400
- Cramer SC, Koroshetz WJ, Finklestein SP. The case for modality-specific outcome measures in clinical trials of stroke recovery-promoting agents. *Stroke*. 2007;38:1393–1395. doi: 10.1161/01.STR.0000260087.67462.80
- Cramer SC, Wolf SL, Adams HP Jr, Chen D, Dromerick AW, Dunning K, et al. Stroke recovery and rehabilitation research: issues, opportunities, and the National Institutes of Health StrokeNet. *Stroke*. 2017;48:813–819. doi: 10.1161/STROKEAHA.116.015501
- Pollock A, Farmer SE, Brady MC, Langhorne P, Mead GE, Mehrholz J, et al. Interventions for improving upper limb function after stroke. *Cochrane Database Syst Rev*. 2014;11:CD010820. doi: 10.1002/14651858.CD010820
- Thieme H, Mehrholz J, Pohl M, Behrens J, Dohle C. Mirror therapy for improving motor function after stroke. *Cochrane Database Syst Rev*. 2012;3:CD008449.
- Champod AS, Frank RC, Taylor K, Eskes GA. The effects of prism adaptation on daily life activities in patients with visuospatial neglect: a systematic review. *Neuropsychol Rehabil*. 2018;28:491–514. doi: 10.1080/09602011.2016.1182032
- Wolf SL, Winstein CJ, Miller JP, Taub E, Uswatte G, Morris D, et al; EXCITE Investigators. Effect of constraint-induced movement therapy on upper extremity function 3 to 9 months after stroke: the EXCITE randomized clinical trial. *JAMA*. 2006;296:2095–2104. doi: 10.1001/jama.296.17.2095
- Dromerick AW, Lang CE, Birkenmeier RL, Wagner JM, Miller JP, Videen TO, et al. Very Early Constraint-Induced Movement during Stroke Rehabilitation (VECTORS): a single-center RCT. *Neurology*. 2009;73:195–201. doi: 10.1212/WNL.0b013e3181ab2b27
- Kwakkel G, Veerbeek JM, van Wegen EE, Wolf SL. Constraint-induced movement therapy after stroke. *Lancet Neurol*. 2015;14:224–234. doi: 10.1016/S1474-4422(14)70160-7
- Chollet F, Tardy J, Alibacher JF, Thalamos C, Berard E, Lamy C, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. *Lancet Neurol*. 2011;10:123–130. doi: 10.1016/S1474-4422(10)70314-8
- Page SJ, Fulk GD, Boyne P. Clinically important differences for the upper-extremity Fugl-Meyer Scale in people with minimal to moderate impairment due to chronic stroke. *Phys Ther*. 2012;92:791–798. doi: 10.2522/ptj.20110009
- Mead GE, Hsieh CF, Lee R, Kutlubaev M, Claxton A, Hankey GJ, et al. Selective serotonin reuptake inhibitors for stroke recovery: a systematic review and meta-analysis. *Stroke*. 2013;44:844–850. doi: 10.1161/STROKEAHA.112.673947
- Maes M, Leonard B, Fernandez A, Kubera M, Nowak G, Veerhuis R, et al. (Neuro)inflammation and neuroprogression as new pathways and drug targets in depression: from antioxidants to kinase inhibitors. *Prog Neuropsychopharmacol Biol Psychiatry*. 2011;35:659–663. doi: 10.1016/j.pnpbp.2011.02.019
- Maya Vetencourt JF, Sale A, Viegi A, Baroncelli L, De Pasquale R, O'Leary OF, et al. The antidepressant fluoxetine restores plasticity in the adult visual cortex. *Science*. 2008;320:385–388. doi: 10.1126/science.1150516
- Scheidtmann K, Fries W, Müller F, Koenig E. Effect of levodopa in combination with physiotherapy on functional motor recovery after stroke: a prospective, randomised, double-blind study. *Lancet*. 2001;358:787–790. doi: 10.1016/S0140-6736(01)05966-9
- Ford G, Farrin A, Hartley S, Cozens A, Holloway I, Meads D, et al. The DARS (Dopamine Augmented Rehabilitation in Stroke) trial. In: 10th UK Stroke Forum Conference. 2015. Abstract.
- Pearson-Fuhrhop KM, Minton B, Acevedo D, Shahbaba B, Cramer SC. Genetic variation in the human brain dopamine system influences motor learning and its modulation by L-Dopa. *PLoS One*. 2013;8:e61197. doi: 10.1371/journal.pone.0061197
- Wang LE, Fink GR, Diekhoff S, Rehme AK, Eickhoff SB, Grefkes C. Noradrenergic enhancement improves motor network connectivity in stroke patients. *Ann Neurol*. 2011;69:375–388. doi: 10.1002/ana.22237
- Barrett KM, Brott TG, Brown RD Jr, Carter RE, Geske JR, Graff-Radford NR, et al; Mayo Acute Stroke Trial for Enhancing Recovery (MASTER) Study Group. Enhancing recovery after acute ischemic stroke with donepezil as an adjuvant therapy to standard medical care: results of a

- phase IIA clinical trial. *J Stroke Cerebrovasc Dis*. 2011;20:177–182. doi: 10.1016/j.jstrokecerebrovasdis.2010.12.009
21. Martinsson L, Hardemark H, Eksborg S. Amphetamines for improving recovery after stroke. *Cochrane Database Syst Rev*. 2007;1:CD002090.
  22. Clarkson AN, Huang BS, Macisaac SE, Mody I, Carmichael ST. Reducing excessive GABA-mediated tonic inhibition promotes functional recovery after stroke. *Nature*. 2010;468:305–309. doi: 10.1038/nature09511
  23. Clarkson AN, Overman JJ, Zhong S, Mueller R, Lynch G, Carmichael ST. AMPA receptor-induced local brain-derived neurotrophic factor signaling mediates motor recovery after stroke. *J Neurosci*. 2011;31:3766–3775. doi: 10.1523/JNEUROSCI.5780-10.2011
  24. Chen CL, Young SH, Gan HH, Singh R, Lao AY, Baroque AC II, et al; CHIMES Study Investigators. Chinese medicine neuroaid efficacy on stroke recovery: a double-blind, placebo-controlled, randomized study. *Stroke*. 2013;44:2093–2100. doi: 10.1161/STROKEAHA.113.002055
  25. Finklestein SP, Caday CG, Kano M, Berlove DJ, Hsu CY, Moskowitz M, et al. Growth factor expression after stroke. *Stroke*. 1990;21(Suppl 1):III122–III124.
  26. Finklestein S, Ren J. Growth factors as treatments for stroke. In: Cramer SC, Nudo RJ, eds. *Brain Repair After Stroke*. Cambridge, UK: Cambridge University Press; 2010:259–266.
  27. Kawamata T, Dietrich WD, Schallert T, Gotts JE, Cocke RR, Benowitz LI, et al. Intracisternal basic fibroblast growth factor enhances functional recovery and up-regulates the expression of a molecular marker of neuronal sprouting following focal cerebral infarction. *Proc Natl Acad Sci USA*. 1997;94:8179–8184.
  28. Ren JM, Finklestein SP. Growth factor treatment of stroke. *Curr Drug Targets CNS Neurol Disord*. 2005;4:121–125.
  29. Kolb B, Morshead C, Gonzalez C, Kim M, Gregg C, Shingo T, et al. Growth factor-stimulated generation of new cortical tissue and functional recovery after stroke damage to the motor cortex of rats. *J Cereb Blood Flow Metab*. 2007;27:983–997. doi: 10.1038/sj.jcbfm.9600402
  30. Belayev L, Khoutorova L, Zhao KL, Davidoff AW, Moore AF, Cramer SC. A novel neurotrophic therapeutic strategy for experimental stroke. *Brain Res*. 2009;1280:117–123. doi: 10.1016/j.brainres.2009.05.030
  31. Jerndal M, Forsberg K, Sena ES, Macleod MR, O'Collins VE, Linden T, et al. A systematic review and meta-analysis of erythropoietin in experimental stroke. *J Cereb Blood Flow Metab*. 2010;30:961–968. doi: 10.1038/jcbfm.2009.267
  32. Cramer SC, Fitzpatrick C, Warren M, Hill MD, Brown D, Whitaker L, et al. The beta-hCG+erythropoietin in acute stroke (BETAS) study: a 3-center, single-dose, open-label, noncontrolled, phase IIA safety trial. *Stroke*. 2010;41:927–931. doi: 10.1161/STROKEAHA.109.574343
  33. Cramer SC, Hill MD; REGENESIS-LED Investigators. Human choriogonadotropin and epoetin alfa in acute ischemic stroke patients (REGENESIS-LED trial). *Int J Stroke*. 2014;9:321–327. doi: 10.1111/ijss.12260
  34. Ehrenreich H, Weissenborn K, Prange H, Schneider D, Weimar C, Wartenberg K, et al; EPO Stroke Trial Group. Recombinant human erythropoietin in the treatment of acute ischemic stroke. *Stroke*. 2009;40:e647–e656. doi: 10.1161/STROKEAHA.109.564872
  35. Li S, Carmichael ST. Growth-associated gene and protein expression in the region of axonal sprouting in the aged brain after stroke. *Neurobiol Dis*. 2006;23:362–373. doi: 10.1016/j.nbd.2006.03.011
  36. Cramer SC, Abila B, Scott NE, Simeoni M, Enney LA; MAG111539 Study Investigators. Safety, pharmacokinetics, and pharmacodynamics of escalating repeat doses of GSK249320 in patients with stroke. *Stroke*. 2013;44:1337–1342. doi: 10.1161/STROKEAHA.111.674366
  37. Cramer SC, Enney LA, Russell CK, Simeoni M, Thompson TR. Proof-of-concept randomized trial of the monoclonal antibody GSK249320 versus placebo in stroke patients. *Stroke*. 2017;48:692–698. doi: 10.1161/STROKEAHA.116.014517
  38. Hess DC, Wechsler LR, Clark WM, Savitz SI, Ford GA, Chiu D, et al. Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Neurol*. 2017;16:360–368. doi: 10.1016/S1474-4422(17)30046-7
  39. Kalladka D, Sinden J, Pollock K, Haig C, McLean J, Smith W, et al. Human neural stem cells in patients with chronic ischaemic stroke (PISCES): a phase I, first-in-man study. *Lancet*. 2016;388:787–796. doi: 10.1016/S0140-6736(16)30513-X
  40. Steinberg GK, Kondziolka D, Wechsler LR, Lunsford LD, Coburn ML, Billigen JB, et al. Clinical outcomes of transplanted modified bone marrow-derived mesenchymal stem cells in stroke: a phase 1/2a study. *Stroke*. 2016;47:1817–1824. doi: 10.1161/STROKEAHA.116.012995
  41. Khedr EM, Ahmed MA, Fathy N, Rothwell JC. Therapeutic trial of repetitive transcranial magnetic stimulation after acute ischemic stroke. *Neurology*. 2005;65:466–468. doi: 10.1212/01.wnl.0000173067.84247.36
  42. Kirtan A, Chen R, Friefeld S, Gunraj C, Pontigon AM, Deveber G. Contralateral repetitive transcranial magnetic stimulation for chronic hemiparesis in subcortical paediatric stroke: a randomised trial. *Lancet Neurol*. 2008;7:507–513. doi: 10.1016/S1474-4422(08)70096-6
  43. Hummel F, Celnik P, Giraux P, Floel A, Wu WH, Gerloff C, et al. Effects of non-invasive cortical stimulation on skilled motor function in chronic stroke. *Brain*. 2005;128(pt 3):490–499. doi: 10.1093/brain/awh369
  44. Hao Z, Wang D, Zeng Y, Liu M. Repetitive transcranial magnetic stimulation for improving function after stroke. *Cochrane Database Syst Rev*. 2013;5:CD008862.
  45. Elsner B, Kugler J, Pohl M, Mehrholz J. Transcranial direct current stimulation (tDCS) for improving activities of daily living, and physical and cognitive functioning, in people after stroke. *Cochrane Database Syst Rev*. 2016;3:CD009645. doi: 10.1002/14651858.CD009645.pub3
  46. Suntrup-Krueger S, Ringmaier C, Muhle P, Wollbrink A, Kemmling A, Hanning U, et al. Randomized trial of transcranial direct current stimulation for poststroke dysphagia. *Ann Neurol*. 2018;83:328–340. doi: 10.1002/ana.25151
  47. Fridriksson J, Rorden C, Elm J, Sen S, George MS, Bonilha L. Transcranial direct current stimulation vs sham stimulation to treat aphasia after stroke: a randomized clinical trial [published online August 20, 2018]. *JAMA Neurol*. <https://jamanetwork.com/journals/jamaneurology/fullarticle/2696529>. doi: 10.1001/jamaneuro.2018.2287
  48. Levy RM, Harvey RL, Kissela BM, Winstein CJ, Lutsep HL, Parrish TB, et al. Epidural electrical stimulation for stroke rehabilitation: results of the prospective, multicenter, randomized, single-blinded everest trial. *Neurorehabil Neural Repair*. 2016;30:107–119. doi: 10.1177/1545968315575613
  49. Meyers EC, Solorzano BR, James J, Ganzer PD, Lai ES, Rennaker RL II, et al. Vagus nerve stimulation enhances stable plasticity and generalization of stroke recovery. *Stroke*. 2018;49:710–717. doi: 10.1161/STROKEAHA.117.019202
  50. Dawson J, Pierce D, Dixit A, Kimberley TJ, Robertson M, Tarver B, et al. Safety, feasibility, and efficacy of vagus nerve stimulation paired with upper-limb rehabilitation after ischemic stroke. *Stroke*. 2016;47:143–150. doi: 10.1161/STROKEAHA.115.010477
  51. Veerbeek JM, Langbroek-Amersfoort AC, van Wegen EE, Meskers CG, Kwakkel G. Effects of robot-assisted therapy for the upper limb after stroke. *Neurorehabil Neural Repair*. 2017;31:107–121. doi: 10.1177/1545968316666957
  52. Lo AC, Guarino PD, Richards LG, Haselkorn JK, Wittenberg GF, Federman DG, et al. Robot-assisted therapy for long-term upper-limb impairment after stroke. *N Engl J Med*. 2010;362:1772–1783. doi: 10.1056/NEJMoa0911341
  53. Wagner TH, Lo AC, Peduzzi P, Bravata DM, Huang GD, Krebs HI, et al. An economic analysis of robot-assisted therapy for long-term upper-limb impairment after stroke. *Stroke*. 2011;42:2630–2632. doi: 10.1161/STROKEAHA.110.606442
  54. Volpe BT, Lynch D, Rykman-Berland A, Ferraro M, Galgano M, Hogan N, et al. Intensive sensorimotor arm training mediated by therapist or robot improves hemiparesis in patients with chronic stroke. *Neurorehabil Neural Repair*. 2008;22:305–310. doi: 10.1177/1545968307311102
  55. Klamroth-Marganska V, Blanco J, Campen K, Curt A, Dietz V, Ettlin T, et al. Three-dimensional, task-specific robot therapy of the arm after stroke: a multicentre, parallel-group randomised trial. *Lancet Neurol*. 2014;13:159–166. doi: 10.1016/S1474-4422(13)70305-3
  56. Mehrholz J, Pohl M, Platz T, Kugler J, Elsner B. Electromechanical and robot-assisted arm training for improving activities of daily living, arm function, and arm muscle strength after stroke. *Cochrane Database Syst Rev*. 2015;11:CD006876.
  57. Mehrholz J, Thomas S, Werner C, Kugler J, Pohl M, Elsner B. Electromechanical-assisted training for walking after stroke: a major update of the evidence [published online June 16, 2017]. *Stroke*. doi: 10.1161/STROKEAHA.117.018018
  58. Duncan PW, Sullivan KJ, Behrman AL, Azen SP, Wu SS, Nadeau SE, et al; LEAPS Investigative Team. Body-weight-supported treadmill rehabilitation after stroke. *N Engl J Med*. 2011;364:2026–2036. doi: 10.1056/NEJMoa1010790
  59. Winstein CJ, Stein J, Arena R, Bates B, Cherney LR, Cramer SC, et al. Guidelines for adult stroke rehabilitation and recovery: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2016;47:e98–e169.



60. Zheng MX, Hua XY, Feng JT, Li T, Lu YC, Shen YD, et al. Trial of contralateral seventh cervical nerve transfer for spastic arm paralysis. *N Engl J Med*. 2018;378:22–34. doi: 10.1056/NEJMoa1615208
61. Hochberg LR, Bacher D, Jarosiewicz B, Masse NY, Simeral JD, Vogel J, et al. Reach and grasp by people with tetraplegia using a neurally controlled robotic arm. *Nature*. 2012;485:372–375. doi: 10.1038/nature11076
62. Chaudhary U, Birbaumer N, Ramos-Murguialday A. Brain-computer interfaces for communication and rehabilitation. *Nat Rev Neurol*. 2016;12:513–525. doi: 10.1038/nrneurol.2016.113
63. Ramos-Murguialday A, Broetz D, Rea M, Lier L, Yilmaz O, Brasil FL, et al. Brain-machine interface in chronic stroke rehabilitation: a controlled study. *Ann Neurol*. 2013;74:100–108. doi: 10.1002/ana.23879
64. Bundy DT, Souders L, Baranyai K, Leonard L, Schalk G, Coker R, et al. Contralateral brain-computer interface control of a powered exoskeleton for motor recovery in chronic stroke survivors. *Stroke*. 2017;48:1908–1915. doi: 10.1161/STROKEAHA.116.016304
65. van der Lee JH, Beckerman H, Lankhorst GJ, Bouter LM. The responsiveness of the Action Research Arm test and the Fugl-Meyer Assessment scale in chronic stroke patients. *J Rehabil Med*. 2001;33:110–113.
66. Dodakian L, McKenzie AL, Le V, See J, Pearson-Fuhrhop K, Burke Quinlan E, et al. A Home-based telerehabilitation program for patients with stroke. *Neurorehabil Neural Repair*. 2017;31:923–933. doi: 10.1177/1545968317733818
67. Lang CE, Macdonald JR, Reisman DS, Boyd L, Jacobson Kimberley T, Schindler-Ivens SM, et al. Observation of amounts of movement practice provided during stroke rehabilitation. *Arch Phys Med Rehabil*. 2009;90:1692–1698. doi: 10.1016/j.apmr.2009.04.005
68. Nudo RJ, Wise BM, SiFuentes F, Milliken GW. Neural substrates for the effects of rehabilitative training on motor recovery after ischemic infarct. *Science*. 1996;272:1791–1794.
69. Chen J, Jin W, Zhang XX, Xu W, Liu XN, Ren CC. Telerehabilitation approaches for stroke patients: systematic review and meta-analysis of randomized controlled trials. *J Stroke Cerebrovasc Dis*. 2015;24:2660–2668. doi: 10.1016/j.jstrokecerebrovasdis.2015.09.014
70. Sarfo FS, Ulasavets U, Opere-Sem OK, Ovbiagele B. Telerehabilitation after stroke: an updated systematic review of the literature. *J Stroke Cerebrovasc Dis*. 2018;27:2306–2318. doi: 10.1016/j.jstrokecerebrovasdis.2018.05.013
71. Veerbeek JM, van Wegen E, van Peppen R, van der Wees PJ, Hendriks E, Rietberg M, et al. What is the evidence for physical therapy poststroke? A systematic review and meta-analysis. *PLoS One*. 2014;9:e87987. doi: 10.1371/journal.pone.0087987
72. Winstein CJ, Wolf SL, Dromerick AW, Lane CJ, Nelsen MA, Lewthwaite R, et al; Interdisciplinary Comprehensive Arm Rehabilitation Evaluation (ICARE) Investigative Team. Effect of a task-oriented rehabilitation program on upper extremity recovery following motor stroke: the ICARE randomized clinical trial. *JAMA*. 2016;315:571–581. doi: 10.1001/jama.2016.0276
73. Lewthwaite R, Winstein CJ, Lane CJ, Blanton S, Wagenheim BR, Nelsen MA, et al. Accelerating stroke recovery: body structures and functions, activities, participation, and quality of life outcomes from a large rehabilitation trial. *Neurorehabil Neural Repair*. 2018;32:150–165. doi: 10.1177/1545968318760726
74. Basso DM, Lang CE. Consideration of dose and timing when applying interventions after stroke and spinal cord injury. *J Neurol Phys Ther*. 2017;41(suppl 3):S24–S31. doi: 10.1097/NPT.0000000000000165
75. Jeffers MS, Corbett D. Synergistic effects of enriched environment and task-specific reach training on poststroke recovery of motor function. *Stroke*. 2018;49:1496–1503. doi: 10.1161/STROKEAHA.118.020814
76. Biernaskie J, Chernenko G, Corbett D. Efficacy of rehabilitative experience declines with time after focal ischemic brain injury. *J Neurosci*. 2004;24:1245–1254. doi: 10.1523/JNEUROSCI.3834-03.2004
77. Saposnik G, Cohen LG, Mamdani M, Pooyania S, Ploughman M, Cheung D, et al; Stroke Outcomes Research Canada. Efficacy and safety of non-immersive virtual reality exercising in stroke rehabilitation (EVREST): a randomised, multicentre, single-blind, controlled trial. *Lancet Neurol*. 2016;15:1019–1027. doi: 10.1016/S1474-4422(16)30121-1
78. Laver KE, Lange B, George S, Deutsch JE, Saposnik G, Crotty M. Virtual reality for stroke rehabilitation. *Stroke*. 2018;49:e160–e161.
79. Kiper P, Szczudlik A, Agostini M, Opara J, Nowobilski R, Ventura L, et al. Virtual reality for upper limb rehabilitation in subacute and chronic stroke: a randomized controlled trial. *Arch Phys Med Rehabil*. 2018;99:834.e4–842.e4. doi: 10.1016/j.apmr.2018.01.023
80. Aminov A, Rogers JM, Middleton S, Caeyenberghs K, Wilson PH. What do randomized controlled trials say about virtual rehabilitation in stroke? A systematic literature review and meta-analysis of upper-limb and cognitive outcomes. *J Neuroeng Rehabil*. 2018;15:29. doi: 10.1186/s12984-018-0370-2
81. Dobkin BH, Dorsch AK. The evolution of personalized behavioral intervention technology: will it change how we measure or deliver rehabilitation? *Stroke*. 2017;48:2329–2334. doi: 10.1161/STROKEAHA.117.016620
82. Dorsch AK, Thomas S, Xu X, Kaiser W, Dobkin BH; SIRRAC Investigators. SIRRAC: an international randomized clinical trial of activity feedback during inpatient stroke rehabilitation enabled by wireless sensing. *Neurorehabil Neural Repair*. 2015;29:407–415. doi: 10.1177/1545968314550369
83. Powell L, Parker J, Martyn St-James M, Mawson S. The effectiveness of lower-limb wearable technology for improving activity and participation in adult stroke survivors: a systematic review. *J Med Internet Res*. 2016;18:e259. doi: 10.2196/jmir.5891
84. Boyd LA, Hayward KS, Ward NS, Stinear CM, Rosso C, Fisher RJ, et al. Biomarkers of stroke recovery: consensus-based core recommendations from the Stroke Recovery and Rehabilitation Roundtable. *Int J Stroke*. 2017;12:480–493. doi: 10.1177/1747493017714176
85. Stinear CM, Byblow WD, Ackerley SJ, Smith MC, Borges VM, Barber PA. PREP2: a biomarker-based algorithm for predicting upper limb function after stroke. *Ann Clin Transl Neurol*. 2017;4:811–820. doi: 10.1002/acn3.488
86. Cassidy JM, Tran G, Quinlan EB, Cramer SC. Neuroimaging identifies patients most likely to respond to a restorative stroke therapy. *Stroke*. 2018;49:433–438. doi: 10.1161/STROKEAHA.117.018844

---

KEY WORDS: brain ■ clinical trials ■ rehabilitation ■ stroke ■ therapeutics